Skip to content

EBITDA at other companies

Relay Therapeutics, Inc. logo
Relay Therapeutics, Inc.RLAY
-$78.09M+6.7%
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
-$116.05M-23.8%
ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
$59.81M+21.8%
Precigen logo
PrecigenPGEN
-$4.9M+77.7%
Arcutis Biotherapeutics, Inc. logo
Arcutis Biotherapeutics, Inc.ARQT
-$8.53M+60.1%
Kodiak Sciences Inc logo
Kodiak Sciences IncKOD
-$55.67M-2.2%

Other financials

Income statement

See full
Revenue$53.0K-97.3%
Operating income-$14.9M-88.7%
Net income-$15.8M-92.6%
EPS (diluted)-$1.20-62.2%

Balance sheet

See full
Cash & equivalents$206.4M+173%
Total debt$584.0K
Total equity$232.3M+318%
Total assets$263.8M+232%

Cash flow

See full
Operating cash flow-$10.9M-60.5%
CapEx--100%
Free cash flow-$2.7M+72.0%

Valuation

See full
Market cap$1.86B+468%

Profitability

See full
Operating margin-183.2%-13.5pp
Net margin71.7%+40.4pp
FCF margin-99.8%-34.2pp

Returns & leverage

See full
Return on equity-34.2%
Debt / equity
Current ratio28.9×+20.0×

Where this comes from

Calculated from Palvella Therapeutics’s reported figures.

$1.8Mebit
$30.0KDepreciation Depletion & Amortization
=-$1.79M

The official record: Palvella Therapeutics’s 10-K, filed March 31, 2026, on SEC EDGAR. View the filing →

Ask your AI about Palvella Therapeutics's ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Palvella Therapeutics's EBITDA?
Palvella Therapeutics (PVLA) reported EBITDA of -$1.79M in Q1 2024.
What does EBITDA mean?
Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.